Preventive cardiology
Adherence to Statins, Subsequent Healthcare Costs, and Cardiovascular Hospitalizations

https://doi.org/10.1016/j.amjcard.2011.01.052Get rights and content

Statins are the primary agents used to decrease low-density lipoprotein cholesterol. Although adherence to statins improves the clinical outcomes, the affect of statin adherence on healthcare costs has not been well studied. To examine the relation among statin adherence, subsequent hospitalizations, and healthcare costs, we conducted a retrospective cohort study of 381,422 patients, aged 18 to 61 years, using an integrated pharmacy and medical claims database. We measured adherence using the medication possession ratio (MPR) for 12 months and the healthcare costs and cardiovascular disease-related hospitalizations during the subsequent 18 months. Of those studied, 258,013 (67.6%) were adherent (MPR ≥80%), 65,795 (17.3%) had an MPR of 60% to 79%, and 57,614 (15.1%) had an MPR of <60%. The adjusted all-cause total healthcare costs were lowest in the adherent group at $10,198 ± $39.4 (mean ± SE) versus $10,609 ± $77.7 (p <0.001) for an MPR of 60% to 79%, and $11,102 ± $84.3 (p <0.001) for an MPR of <60%. The adherent group had greater statin costs at $838 ± $1.0 versus $664 ± $2.0 (p <0.001) and $488 ± $2.2 (p <0.001). When evaluated by 5 levels of MPR, 0% to 59% and increments of 10% >60%, the adjusted total healthcare costs were lowest for the MPR 90% to 100% group and significantly greater statistically (p <0.001) for each lower level of adherence. Compared to the statin-adherent patients, cardiovascular disease-related hospitalizations were more likely for the patients with an MPR of 60% to 79% (odds ratio 1.12, 95% confidence interval 1.08 to 1.16) and an MPR of 0% to 59% (odds ratio 1.26, 95% confidence interval 1.21 to 1.31). In conclusion, statin adherence is associated with reductions in subsequent total healthcare costs and cardiovascular disease-related hospitalizations.

Section snippets

Methods

The source of data was the Medco National Integrated database, which contains 30 months of medical and pharmacy claims data for approximately 13 million patients enrolled in >450 different health plans, including fee-for-service, preferred provider, and managed care plans sponsored by insurance companies, employers, and government organizations. The medical claims contain all inpatient, outpatient, nursing home, laboratory, and diagnostic testing claims the health plan has received. The

Results

Our analysis identified 381,422 patients who met the inclusion criteria. The patient demographics are listed in Table 1. The mean level of adherence in year 1 was 43.1% in the MPR <60% group, 71.3% in the 60% to 79% adherence group, and 94.5% in the MPR ≥80% adherent group.

Overall, the most common co-morbidities were hypertension, coronary artery disease, and diabetes mellitus. Also, 8.6% of the patients had a history of depression. The adherent group was older, more likely to be men, and had a

Discussion

The objective of the present study was to evaluate whether adherence to statins for 12 months was associated with the subsequent healthcare costs and CVD-related hospitalizations. In the present large, national sample of insured patients receiving statins, we found approximately 1/3 of the 381,422 patients were nonadherent to statins in the baseline year and that nonadherence was associated with a $400 to $900 per patient greater total healthcare cost and increased likelihood of a CVD-related

Acknowledgment

We thank Lorraine Tully, RHIT (Medco Health Solutions), for assistance with medical coding; Ray Brown, BSPharm (Medco Health Solutions), for analytic contributions; and Diane Graul (Medco Health Solutions) for administrative support. We thank Steven Haffner, MD and Cindy Fenton, MD (Medco Health Solutions Consultants), for assistance with all study phases.

References (21)

There are more references available in the full text version of this article.

Cited by (0)

View full text
Copyright © 2011 Elsevier Inc. All rights reserved.